BIOMACROMOLECULES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2022-04-07 xing07

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：聚合物表征
经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的

1 0

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2020-05-17 ms887994580797846

审稿速度:2.0
经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。

144 0

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2020-03-14 ms1145759477415829

审稿速度:1.0
经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。

155 0

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2019-12-29 ms4294801609865205

这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。

152 0

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2018-03-17 hongweicheng

温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表:
做哪方面的?

elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?

357 0

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2018-03-15 elsa2005

做哪方面的?hongweicheng 2018-03-14 00:00:00 发表:
写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多

hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多

398 0

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2018-03-14 hongweicheng

写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表:
投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了

hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了

355 0

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2018-01-16 hongweicheng

投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了

384 0

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2017-07-16 zheyang

还是5分多,虽然没有大变化,能稳定在些,也算是中上等

441 0

[GetPortalCommentsPageByObjectIdResponse(id=1209384, encodeId=8780120938491, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：聚合物表征 经验分享：1.31submit 3.1 comments back（1大修，2小修） 3.25 revised 3.28 accepted 4.7 online 核酸递送方向，reviewers的意见基本都很专业，不会刻意为难，能补的实验就补，不赞同的地方就解释清楚，整个过程还是蛮顺利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e032165541, createdName=xing07, createdTime=Thu Apr 07 21:52:39 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860637, encodeId=d54286063e48, content=审稿速度:2.0 经验分享：两个大修两个小修，修改后接受，这个期刊对材料表征要求很高，对动物实验要求不高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Sun May 17 07:39:27 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858390, encodeId=c5cd85839014, content=审稿速度:1.0 经验分享：这个期刊真心的好，submitted一个月后给审稿意见，大修，审稿人一大两小，用了一周回复，第三天就accept了。真心的快。不过审稿人的意见很专业而且问的很细致，对创新性要求很高，对机理部分需要特别解释清。总之经常在这个网站看投稿经验，终于能回馈给大家，希望有所帮助。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Sat Mar 14 20:25:14 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=856304, encodeId=dbd685630474, content=这个杂志非常好，在化学领域的第一篇，一个半月回审稿意见，一个大修一个小修，未要求补实验，修改7天后返回，2天后接受，当天直接 accepted manuscript上网。希望杂志越来越好。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Sun Dec 29 20:34:53 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553780, encodeId=01d4553e80df, content=温敏载体.抗肿瘤elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, beContent=elsa2005 2018-03-15 00:00:00 发表: 做哪方面的?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553700, encodeId=2d78553e00a7, content=做哪方面的?hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, beContent=hongweicheng 2018-03-14 00:00:00 发表: 写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多, objectType=tool_impact_factor, channel=null, level=null, likeNumber=398, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/30/9a7b5a7a9a26b411d8e4a0cc95370ed4.jpg, createdBy=cb7b111071, createdName=elsa2005, createdTime=Thu Mar 15 00:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553664, encodeId=5fff553664e7, content=写完这个状态.又过了三天就接收了.当天就online.ACS的效率比Wiley快很多hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=hongweicheng 2018-01-16 18:10:00 发表: 投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Mar 14 00:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551483, encodeId=48b255148384, content=投了一篇.前几天修回去了.还没消息呢.期待这次快收了吧.在其他期刊那里走了好几圈了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Tue Jan 16 18:10:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544212, encodeId=26e55442121c, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=441, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516192, encodeId=6a975161926d, content=审稿速度:2.0 经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=510, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0c71657934, createdName=琉璃, createdTime=Wed Oct 21 09:00:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]

2015-10-21 琉璃

审稿速度:2.0
经验分享：一篇材料性质影响细胞行为的文章，八月初投稿，九月二十三号收到审稿意见。三个审稿人，主编只返回了两个意见，可能是因为第三个审稿人没有按时提交。都是小修，补充了三个次要数据的实验，添加了一些描述，回答了一个问题。提交后第三天就接收了。感觉这个期刊要求对于实验现象的描述、解释与讨论很重要，最好能在disscussion中充分讨论并多引一些相关文献来佐证。

510 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务